MUC4

MUC4

A gene on chromosome 3q29 that encodes an integral membrane glycoprotein found on cell surfaces, which may play a role in tumour progression by repressing apoptosis. MUC4 may alter cellular behaviour through both its anti-adhesive effects on cell-cell and cell-extracellular matrix interactions and its ability to act as a ligand for ERBB2, the phosphorylation of which plays an important role in epithelial cell proliferation and differentiation.
References in periodicals archive ?
4) Recently, immunohistochemistry specific to various mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC6, MUC7, and MUC8) has been used to evaluate the mucin phenotypes of gastric cancer.
Expression of membrane-associated mucins MUC1 and MUC4 in major human salivary glands.
Experimental studies indicate that tumour overexpression of MUC4 and also CD44 may be further elements that interfere with adequate binding of trastuzumab to its target receptor sites to promote resistance [19].
ABSTRACT : In 2004, Jorgensen and coworkers proposed the MUC4 gene as a candidate gene of enterotoxigenic Escherichia coli (ETEC) F4ab/ac receptor in piglets and a mutation of G [right arrow] C in intron 7 of MUC4 was identified to be associated with the ETEC F4ab/ac adhesion phenotypes.
8-13) MUC4 and MUC16 are transmembrane glycoproteins that, through alterations in the expression and nature of glycosylation, can affect cell adhesion, protein-protein interaction, and immune responses, all of which can facilitate tumor development and metastasis.
Examples of potentially relevant mechanisms include: disruption of the trastuzumab-HER2 interaction which has been demonstrated, for example, to occur by the overexpression of MUC4, a sialomucin complex overexpressed in some breast tumours [49,50]; increased signalling through other members of the HER family, such as HER1, to downstream messenger pathways [51,52]; compensatory signalling through other receptor types such as insulin-like growth factor-I receptor (IGF-IR) which is able to inhibit HER2 sensitivity to trastuzumab through crosstalk [53,54]; or modulation of downstream signalling pathways for example via PTEN deficiency [14] or downregulation of p27(Kip1) [55].
Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.
2, CK [cytokeratin] 7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/ SMAD4, CDX2, pVHL [von Hippel-Lindau tumor suppressor gene protein], S100P, IMP-3 [insulin-like growth factor 2 messenger RNA binding protein 3], maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA [prostate stem cell antigen], MOC31, CEA [carcinoembryonic antigen], and CA19-9 [cancer antigen 19-9]) in the diagnosis of ductal adenocarcinoma of the pancreas by using 60 cases of pancreatic DAC on routine and tissue microarray (TMA) sections.
Immunohistochemical labeling of several genes including CDKN1A, (12) PSCA, (7,13) MMP7, (14) MUC4, (15,16) CLDN18, (17) ANXA2, (18) BIRC5, (19,20) MUC5, (7) and S100P (21) in multiple PanIN lesions has shown a progressive increase in their expression from low- to high-grade PanINs and leading into invasive cancer.
To evaluate the relationship between MUC4 overexpression and long-term survival in patients with NSCLC.